Odd: Sold Aerospan NDA in 2009 and Bought Viibryd NDA in 2011
9/20/12 MARLBOROUGH, Mass.--(BUSINESS WIRE)--
Acton Pharmaceuticals, Inc. (Acton) announced today that the U.S. Food and Drug Administration (FDA) has approved
the sNDA (Supplemental New Drug Application) for AEROSPAN® (flunisolide HFA, 80 mcg) Inhalation Aerosol, a
hydrofluoroalkane (HFA) orally inhaled corticosteroid indicated for the maintenance treatment of asthma as a
prophylactic therapy in adult and pediatric patients 6 years of age and older. With this approval, Acton is now planning to
launch AEROSPAN in early 2013 into the $8.3 billion U.S. inhaled steroid market1.
The AEROSPAN New Drug Application (NDA) was acquired by Acton in 2009 under a licensing
agreement with Forest Laboratories, Inc. (FRX) at which time Acton assumed all responsibilities associated with the
development and commercialization of AEROSPAN.
4/12/11 NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) (“Forest”) today announced that its indirect wholly-owned subsidiary, Magnolia Acquisition Corp. (“Magnolia”), has accepted for purchase all of the securities validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of, and certain outstanding notes and warrants convertible into or exercisable for the common stock of, Clinical Data, Inc. (NASDAQ: CLDA) (“Clinical Data”). The offering period and withdrawal rights expired at 12:00 midnight, New York City time on Monday April 11, 2011. American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, has advised Forest that as of the expiration of the offering period, approximately 27,868,256 shares of Clinical Data common stock; 93,556 2005 Warrants; 113,817 2006 Warrants; 757,461 2008 Warrants; 1,527,650 Series A 2009 Warrants; 1,527,650 Series B 2009 Warrants; and $50,000,000 aggregate principal amount of convertible notes, convertible into 6,110,599 shares of Clinical Data common stock, were validly tendered and not validly withdrawn prior to the expiration of the offering period. The securities validly tendered and not validly withdrawn represent approximately 82.8% of the outstanding shares of Clinical Data common stock on a fully-diluted basis.